Owing to the fact that the overexpression of efflux transporters (P-gp, BCRP) in breast cancer cells to TAM therapy constitutes a major problem in oncology practice27, the inhibitors of P-gp/BCR transporters could increase drug exposure, yet with increased side effects23. Here, PGP is linked to breast carcinoma.